# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1) (Mark One) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2012 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to to Commission file number 000-28489 ADVAXIS, INC. (Exact name of registrant as specified in its charter) 02-0563870 **Delaware** (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 305 College Road East, Princeton, NJ 08540 (Address of principal executive offices) (609) 452-9813 (Registrant's telephone number) (Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  $\boxtimes$  No  $\square$ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  $\boxtimes$  No  $\square$ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer  $\Box$ Accelerated filer  $\Box$ Non-accelerated filer  $\Box$ Smaller Reporting Company ⊠ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⊠

The number of shares of the registrant's common stock, \$0.001 par value, outstanding as of June 11, 2012 was 363,451,168

#### **EXPLANATORY NOTE**

This Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarterly period ended April 30, 2012 (the "Form 10-Q"), originally filed by Advaxis, Inc. on June 14, 2012, is being filed solely for the purpose of amending and restating Exhibit 10.3 of the Form 10-Q.

The Form of Project Agreement by and between Numoda Corporation and Advaxis, Inc. filed as Exhibit 10.3 to the Form 10-Q is being replaced with the executed version of the Project Agreement by and between Numoda Corporation and Advaxis, Inc., dated as of July 1, 2009. Part II, Item 6 is being amended and restated to reflect that Exhibit 10.3 is filed herewith.

Except as described above, no other changes have been made to the Form 10-Q. This Amendment does not amend, update or change the financial statements or disclosures in the Form 10-Q and does not reflect events occurring after the filing of the Form 10-Q.

### PART II - OTHER INFORMATION

### Item 6. Exhibits.

10.3*	Project Agreement, dated as of July 1, 2009, by and between Numoda Corporation and Advaxis, Inc.
31.1*	Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

<sup>\*</sup> Filed herewith

#### **SIGNATURES**

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ADVAXIS, INC.

Registrant

Date: June 26, 2012 By: /s/ Thomas Moore

Thomas Moore

Chief Executive Officer and Chairman of the Board

By: /s/ Mark J. Rosenblum

Mark J. Rosenblum

Chief Financial Officer, Senior Vice President and Secretary

### EXHIBIT INDEX

Exhibit No.	Document Description						
10.3*	Project Agreement, dated as of July 1, 2009, by and between Numoda Corporation and Advaxis, Inc.						
31.1*	Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002						
31.2*	Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002						
32.1*	Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002						
32.2*	Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002						
* Filed herewith							

PROTOCOL NUMBER: Lm-LLO-E7-07 & 15, Two Trials

#### **NUMODA**

### PROJECT AGREEMENT FOR PROTOCOL #'s: Lm-LLO-E7-15 and Lm-LLO-E7-07 (Two Trials — TRIAL 1 in India, and TRIAL 2 in the U.S.

Protocol Number: Lm-LLO-E7-15 (conducted in India)

Protocol Title: A Randomized, Active Therapy Controlled Phase 2 Study to Assess the Safety and

Efficacy of ADXS11-001 with and without Cisplatin as a 2<sup>nd</sup> Line Therapy for the Treatment of

Recurrent Cervical Cancer.

Protocol Number: Lm-LLO-E7-07 (conducted in the United States)

Protocol Title: A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety

and Efficacy of Lovaxin C for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3.

Pursuant to the Master Agreement entered into by Advaxis, Inc. ("ADVAXIS") and Numoda Corporation ("Numoda") on June 19, 2009 ("MA"), this Project Agreement (PA) and attachments, including:

- A. Description of Services Project Specifications
- B. Integration Assumptions; Systems, and Reporting Tools
- C. Project Budget
- D. Payment Schedule/Terms
- E. Transfer of Regulatory Obligations

is entered into and is effective on the Effective Date shown below. Only when specified in the MA, the parties agree that Numoda shall perform the Project Agreement in accordance with and is subject to all the terms and conditions of the MA. The Project Agreement is Incorporated in and made a part of the MA. In the event that a discrepancy exists between the terms of the MA and this PA, this PA shall supersede.

Effective Date: July 1, 2009

The parties agree as follows:

- 1. <u>Scope of Work</u>: Numoda agrees to provide services for this Study ("Project") as outlined in Attachment A (Description of Services Project Specifications). The Parties understand Attachments A, B, C and D may need some adjustments after the date of signing this Project Agreement, in order to reflect any material differences between the protocol provided to Numoda and the final protocol. ADVAXIS transfers to Numoda the obligations listed in Attachment E in accordance with 21 CFR §312.52.
- 2. <u>Payment</u>: Payments will be made in accordance with Attachment D. Upon final reconciliation, additional services not included in the scope of work, that was mutually agreed to in writing; and having been done, will be billed to ADVAXIS, and any overpayment attributable to services not rendered or costs not incurred, will be refunded to ADVAXIS.
- 3. <u>Term</u>: The term of this Project Agreement shall commence on the Effective Date and shall continue until the Project as described in this Project Agreement is completed, unless this Project Agreement is terminated earlier in accordance with the MA.
- 4. <u>Contact</u>: Until further notice and for the purpose of this Project Agreement, Numoda's contact within ADVAXIS will be John Rothman, and ADVAXIS' contact within Numoda will be Mike Dempsey, the Project Controller.

ADVAXIS, INC.

PROTOCOL NUMBER: Lm-LLO-E7-07 & 15, Two Trials

For ADVAXIS:

EVP: Science & Operations

July 8, 2009

Title:

Date:

For Numoda Corporation:

COO

July 8, 2009

Sign:	/s/ John Rothman	Sign:	/s/ Ann Vurimindi
Print:	John Rothman	Print:	Ann Vurimindi

Title:

Date:

### Attachment A: DESCRIPTION OF SERVICES - PROJECT SPECIFICATIONS

Overall Assumptions	India Trial	US Trial
Protocol Number	Lm-LLO-E7-15	Lm-LLO-E7-07
Study Phase	Phase II, India	Phase II, U.S.
Compound	ADXS11-001	ADXS11-0011
Number of Sites	12	20
Number of Patients Screened	122	88
Number of Patients Enrolled	110	80
Number of Patients Completed	110	80
Country	India Only	USA Only
Startup (Number of Weeks) <i>From signed PA to FPFV</i> Recruitment (Number of Weeks)	13	8.5
(Tria1 #2 totals 36 months for	13	0.5
Treatment (Number of Weeks) Recruitment + Treatment)	13	26
Closeout (Number of Weeks)	52	130
Closcout (Number of Weeks)	13	8.5
		0.5
Total Project Duration (Weeks)	91 (21 Mo's)	173 (40 Mo's)
GC Project Management Assumptions		
Number of Status Reports	Unlimited within the	Unlimited within the
Number of Kick Off Meetings	scope	scope
Number of Investigator Meetings	1	1
Number of Newsletters	1	0
Number of Teleconferences (1 Hour Calls)	21	36
	91	173
Monitoring Assumptions		
Qualification Visits	12	22
Site Initiation Visits	12	20
Interim Monitoring Visits	97	312
Closeout Visits	12	20
Information/Data Management Assumptions		
Total Number of CRF Pages per Patient	100	90
Number of Unique CRF Pages per Patient	20	22
Total Number of CRF Pages	11,904	11,688
	Unlimited within the	Unlimited within the
Total Number of Queries	scope	scope
Total Number of Users	30	50
Number of Interim Analyses	1	2
Con Meds per Patient	10	10
Diseases per Patient	10	10
AE's per Patient	10	10
The open ration	10	10
Biostats Assumptions		
Statistical Analysis Plan	1	1
Tables	24	24
Listings	30	30
Figures	6	6
Final Study Report	1	1
Safety Assumptions	40	45
SAE's	40	15
Safety Database	1	1
Estimated Timeline		
Contract Signed	Jul-09	Jul-09
First Patient Enrolled	Oct-09	Sep-09
Last Patient Enrolled	Jan-10	Mar-10
Last Patient Out	Jan-11	Sep-12
Final Clinical Study Report	Apr-11	Nov-12
I mai Omneu otaay report	11h1-11	1404-17

Note: The Project Budget in Attachment C is based on the specifications and integration assumptions listed here on Attachment A, and in Attachment B.

## Attachment B: INTEGRATION ASSUMPTIONS

		Numoda
<b>Integrations Assumpt</b>		
Single Integrated Porta		1
Custom Integration and		3
Ongoing Consolidation		1
Systems and Reportir	nting, Contracting (Vendor Negotiation, Documentation, Monitoring)	1
2	Administration (4 Tool Sets)	1
otare up of regulatory	Project Timelines	-
	Site Launch Logistics System (SLLS)	
	Communication Plan	
	Roles and Responsibilities	
Clinical Project Accou	nting Systems (3 Tool Sets)	1
	Key Value Tracking	
	Percentage of Completion Reporting	
Dl	CPA Procedures	1
Planning, Procurement	, Contracting (4 Tool Sets) Vendor Contract Status	1
	Business Analysis Report	
	Key Value Points	
	Business Integration	
Screening and Enrollm	ent Reporting Tools (9 Tool Sets)	1
Ü	Executive Summary	
	Enrollment Status	
	Subject Status	
	Early Termination	
	Screen Failure	
	Enrollment by Site	
	Patient Source Summary Site Info	
	Team Contact Info	
Document Managemer		1
Document Managemen	Protocol and Amendments	-
	Newsletters	
	Training Materials	
	Project Management	
	Waivers	
	Upload	
	Remove File	
Monitoring Systems (7		1
	Data View	
	Monitoring Summary Query Tracking	
	Comments	
	Supplies Status For Monitors	
	Sync Status Report	
	Trip Report Management	
Data Management and	Integrations (17 Tool Sets)	1
	Data View	
	IVR Reconciliation	
	Data Extractor	
	Edit Checks	
	Query Frequency	
	Edit Check Frequency Query Status Summary	
	Coding System	
	PI Sign-Off	
	AE/Cmed/Med HX Summary	
	Various Lab Reconciliation Tools (7)	
Early Safety Signal De	tection System (5 Tool Sets)	1
	AE/SAE	
	Subject Safety Reports	
	Subject Status	
	Early Terminators	
0 11 3.5	Site Info	_
Supplies Management		1
	Site Supplies Status Site Transaction History	

Site Supplies Summary Project Management Administration Tools (11 Tool Sets)

User Management Login History Failed Logins

Database SQL Tools

IVR Database View

Team Contact Management

Message System Management

Shipment Address Management Document Group Management Trip Report Administration

IVRS Administration

### **Attachment C:**

Care Trip. Regularity & Situs Management         \$ 122,36         \$ 2,000,000           Sair Uly, Regulary & Situs Management         \$ 2,546,101         \$ 2,000,000           Project Management         \$ 2,546,001         \$ 2,000,000           Data Management         \$ 2,000,000         \$ 2,000,000         \$ 2,000,000           Steffy, Medical & Scientific Services         \$ 145,000         \$ 160,000			In	dia Trial	<b>US Trial</b>
Monitoring	Standardized Professional Fees				
Project Management         \$ 151,40 g         395,959           Data Management         \$ 226,00 g         187,80 g           Safery, Medical & Scientific Services         \$ 153,00 g         187,80 g           Medical Writing         161,50 g         155,00 g         160,00 g           Medical Writing         Total Standardized Professional Fee         180,00 g         160,00 g           Products         Efficiency Cender         98,04 g         180,00 g           Products         Station         3 0,45 g         5,54 g           Role-Based Borals- Commercing to Interruperable Neural Neuroling         8 10,00 g         3 33,33 g           Role-Based Darials Commercing to Interruperable Neural Neuroling         8 12,00 g         3 33,33 g           Clinical Project Accounting Word Management & Financial Reconciliation         8 12,00 g         3 33,33 g           Clinical Project Accounting System         5 16,00 g         3 25,53 g           Real Time Reporting Book (with Document Management System)         8 12,00 g         3 7,72 g           Real Time Reporting Book (with Document Management System         9 12,00 g         3 3,35 g           Real Time Reporting Book (with Document Management System         1 10,00 g         3 3,35 g           Real Time Reporting Book (with Document Management System         1 10,00 g	Start Up, Regulatory & Sites Management		\$	122,362	\$
Date Management         \$ 220,000         \$ 183,446           Biostalistics         \$ 145,600         \$ 167,000           Medical Writing         Total Standardized Professional Pees         \$ 16,000         \$ 6,000           Product         Biostalistics         \$ 12,000         \$ 2,000           Biographic Medical Writing         Total Standardized Professional Pees         \$ 10,24885         \$ 2,000           Product           Product           Biographic Medical Writing         \$ 30,457         \$ 55,404           All Custom Complete Integration and Interoperability         \$ 30,457         \$ 21,003         \$ 3,323           Ongoing Consolidation and Reconciliation         \$ 16,658         \$ 22,503         \$ 3,323           Clinical Project Accounting Vendor Management Stinancial Reconciliation         \$ 16,658         \$ 22,503         \$ 5,548           Steel Time Reporting Book with Document Management System         \$ 16,658         \$ 22,503         \$ 5,548           Steel Time Reporting Book with Document Management System         \$ 18,000         \$ 12,000         \$ 5,554           Real Time Reporting Book with Document Management System         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000	Monitoring		\$		\$ 1,268,014
Safety, Medical & Scientific Services         \$ 1,34,46         \$ 163,464         \$ 163,046         \$ 167,000         \$ 167,000         \$ 163,000         \$ 163,000         \$ 160,000         <	Project Management		\$	151,469	\$ 396,950
Biostatistists	Data Management		\$		\$ 289,759
Medical Writing	Safety, Medical & Scientific Services		\$	79,898	\$ 183,446
Total Standardized Professional Fees   1,024,885   5,0616,777   1,000   1,00			\$	145,460	\$ 167,804
Products	Medical Writing		\$	45,000	\$ 60,000
Products	Т	otal Standardized Professional Fees	\$	1,024,885	\$ 2,616,577
Products   Section   Sec		Efficiency Credit	\$	(96,848)	
Role-Based Portals Connecting to Interoperable Neural Network   \$ 3,045   \$ 5,5404   \$ 1,000		sub-total	\$	928,037	
All Custom Complete Integration and Interoperability Ongoing Consolidation and Reconciliation Ongoing Consolidation and Reconciliation Circening and Enrollment System Site Compliance Tools (with Document Management System) Site Compliance Tools Site Compliance Site System Site System Site Site Site Site Site Site Site Site					
Ongoing Consolidation and Reconciliation         \$ 21,003         \$ 98,046           Clinical Project Accounting Vendor Management & Financial Reconciliation         \$ 16,638         \$ 25,339           Site Compliance Tools         \$ 16,638         \$ 25,339           Site Compliance Tools         \$ 34,555         \$ 5,548           Real Time Reporting Tools (with Document Management System)         \$ 28,945         \$ 6,814           Real Time Reporting Tools (with Document Management Propertions)         \$ 35,032         \$ 57,294           Interparent Meb-Based Monitoring system (with Centralized Trip Reports)         \$ 35,819         \$ 90,508           Early Safety Signal Detection System         \$ 19,102         \$ 33,353           Interport Accounting System         \$ 19,102         \$ 33,353           INRS Diary Activities         \$ 19,102         \$ 33,353           INRS Diary Activities         Total Product         \$ 18,102         \$ 78,176           INRS Diary Activities         Total Product         \$ 10,002         \$ 78,176           Investigator Meeting Travel         \$ 40,605         \$ 1,002,560           Investigator Meeting Organization         \$ 49,605         \$ 1,002,560           Investigator Meeting Organization         \$ 84,005         \$ 1,002           Investigator Meeting Organization         \$ 84,	Role-Based Portals Connecting to Interoperable Neural Network		\$	30,457	\$
Clinical Project Accounting Vendor Management & Financial Reconciliation         \$ 5,548         \$ 98,046           Screening and Enrollment System         \$ 16,858         \$ 25,359           Site Compliance Tools         \$ 34,659         \$ 5,5548           Real Time Reporting Tools (with Document Management System)         \$ 27,022         \$ 5,7072           Integrated, Web-Based Monitoring system (with Centralized Trip Reports)         \$ 28,945         \$ 5,8048           Larly Safety Signal Detection System         \$ 35,819         \$ 5,224           Clinical Project Accounting System (with Centralized Trip Reports)         \$ 35,819         \$ 90,508           Clinical Project Accounting System         \$ 19,192         \$ 33,833           IVES System for Supplies and Re-Supply Logistics Management         \$ 19,192         \$ 122,963           IVES Diary Activities         \$ 10,002         \$ 122,963           IVES Diary Activities         \$ 10,002         \$ 122,963           IVES Diary Activities         \$ 294,142         \$ 122,963           IVES Diary Activities         \$ 10,002         \$ 122,963           IVES Diary Activities         \$ 294,102         \$ 124,002           IVES Diary Activities         \$ 294,002         \$ 124,002           IVES Diary Activities         \$ 21,002         \$ 1,002,502			\$	45,943	\$
Screening and Enrollianet System         \$ 16,686         \$ 25,358           Site Compliance Tools         \$ 34,655         \$ 55,548           Real Time Reporting Tools (with Document Management System)         \$ 27,202         \$ 55,748           Early Safety Signal Detections System (with Centralized Trip Reports)         \$ 32,035         \$ 5,814           Early Safety Signal Detection System         \$ 32,035         \$ 90,508           Clinical Project Accounting System         \$ 60,264         \$ 20,208           Interport Project Accounting System for Supplies and Re-Supply Logistics Management         Total Product         \$ 60,264         \$ 12,208           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           Pass-Through Expenses (Estimated)         Total Product         \$ 1,002,560         \$ 1,002,560           Investigator Fees         \$ 45,650         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560         \$ 1,002,560			\$	21,003	\$
Site Compliance Tools         \$ 34,659         \$ 5,548           Real Time Reporting Tools (with Document Management System)         \$ 27,202         \$ 57,072           Integrated, Web-Based Monitoring system (with Centralized Trip Reports)         \$ 32,053         \$ 57,294           Clinical Project Accounting System         \$ 35,819         \$ 90,508           Clinical Project Accounting System         \$ 19,192         \$ 33,353           IVRS System for Supplies and Re-Supply Logistics Management         \$ 19,192         \$ 33,353           IVRS Diary Activities         Total Product         40,891         \$ 78,3176           Res Trough Expenses (Estimated)         Total Product         10,474         \$ 783,176           Pass-Through Expenses (Estimated)         Free         Free         Pree           Investigator Fees         \$ 496,650         \$ 1,002,560         \$ 1,002,560           Investigator Meeting Organization         \$ 2,100         \$ 2,100         \$ 1,002,560           Investigator Meeting Organization         \$ 2,300         \$ 2,300         \$ 370,448           Investigator Meeting Travel         \$ 2,300         \$ 3,450         \$ 3,100         \$ 3,100           Investigator Meeting Travel         \$ 2,300         \$ 3,100         \$ 1,200         \$ 2,200           Meetings and Teleconfer	Clinical Project Accounting Vendor Management & Financial Reconciliation		\$	55,498	\$
Real Time Reporting Tools (with Document Management System)         \$ 27,202         \$ 5,7072           Integrated, Web-Based Monitoring system (with Centralized Trip Reports)         \$ 28,945         \$ 68,814           Early Saffety Signal Detection System         \$ 35,819         \$ 50,026           Clinical Project Accounting System for Supplies and Re-Supply Logistics Management         \$ 19,192         \$ 33,333           INRS Diary Activities         \$ 60,264         \$ 122,963           INRS Diary Activities         Total Products         \$ 407,819         \$ 783,176           Report Management System for Supplies and Re-Supply Logistics Management         \$ 101,000         \$ 783,176           INRS Diary Activities         Total Products         \$ 407,601         \$ 783,176           INRS Diary Activities         Total Products         \$ 407,601         \$ 783,176           Investigator Mecting Created System for Supplies and Research System         \$ 100,001         \$ 1,000         \$ 1,000           Investigator Meeting Organization         \$ 21,000         \$ 1,000         \$ 1,000         \$ 1,000           Investigator Meeting Travel         \$ 40,650         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000         \$ 1,000			\$	16,858	\$ 25,359
Integrated, Web-Based Monitoring system (with Centralized Trip Reports)         \$ 38,945         \$ 68,814           Early Safery Signal Detection System         \$ 32,053         \$ 79,296           Clinical Project Accounting System         \$ 19,192         \$ 33,353           IVRS Diary Activities         \$ 10,264         \$ 122,963           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           IVRS Diary Activities         Befficiency Cred to (113,749)         \$ 783,176           IVRS Diary Activities         Sub-total State (113,749)         \$ 783,176           IVRS Diary Activities         Befficiency Cred to (113,749)         \$ 783,176           IVRS Diary Activities         Sub-total State (113,749)         \$ 783,176           IVRS Diary Activities         Sub-total State (113,749)         \$ 783,176           Pass-Through Expenses (Estimated)         Free         Free           Investigator Meeting Organization         \$ 1,000,256         \$ 1,000,256           Investigator Meeting Organization         \$ 12,000         \$ 33,415           Investigator Meeting Organization         \$ 12,000         \$ 34,565           Investigator Meeting Organization         \$ 1,000         \$ 34,505           Investigator Meeting Organization         \$ 1,000         \$ 1,000 <tr< td=""><td>Site Compliance Tools</td><td></td><td>\$</td><td>34,659</td><td>\$ 55,548</td></tr<>	Site Compliance Tools		\$	34,659	\$ 55,548
Early Safety Signal Detection System         \$ 32,03         \$ 72,294           Clinical Project Accounting System         \$ 35,191         \$ 90,508           Interoperable System for Supplies and Re-Supply Logistics Management Interoperable System for Supplies and Re-Supply Logistics Management         \$ 60,264         \$ 132,963           IVRS Diary Activities         Total Product         \$ 407,891         \$ 783,176           Pass-Through Expenses (Estimated)         Fefficiency Credit         \$ 101,749         * 178,176           EDC         Fere         Free         Free           Investigator Meeting Organization         \$ 496,659         \$ 1,002,560           Investigator Meeting Travel         \$ 476,659         \$ 1,002,560           Investigator Meeting Reting Travel         \$ 476,659         \$ 1,002,560           Investigator Meeting Pravel         \$ 476,659         \$ 1,002,560           Investigator Meeting Retings and Electroference         \$ 476,659         \$ 1,002,560           Travel to Client Meetings         \$ 1,000         \$ 33,444           Travel for Audit Visits         \$ 1,000         \$ 1,000           Travel for Audit Visits         \$ 1,000         \$ 1,000           Pitzup Sepses         \$ 2,000         \$ 5,000           Propose         \$ 2,000         \$ 1,000	Real Time Reporting Tools (with Document Management System)		\$	27,202	\$ 57,072
Clinical Project Accounting System         \$ 35,81         \$ 90,508           Interoperable System for Supplies and Re-Supply Logistics Management         \$ 19,192         \$ 333,533           IVRS Diary Activities         \$ 60,264         \$ 122,963           IVRS Diary Activities         Total Products         \$ 47,891         \$ 783,176           Pass-Through Expenses (Estimated)           Free         Free         Free           Investigator Fees         \$ 496,650         \$ 1,002,560           Investigator Meeting Organization         \$ 47,565         \$ 49,650           Investigator Meeting Travel         \$ 47,565         \$ 49,650           Monitor Travel         \$ 47,565         \$ 49,650           Travel to Client Meetings         \$ 47,565         \$ 49,650           Travel to Training Meetings         \$ 1,050         \$ 1,050           Travel to Training And Teleconferences         \$ 1,260         \$ 1,050           Travel to Glient Meetings         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 1,260         \$ 1,050           Travel to Training Meetings         \$ 1,260         \$ 5,745           Travel to Training And Teleconferences         \$ 1,260         \$ 1,260           Pinting, Shipping and Other	Integrated, Web-Based Monitoring system (with Centralized Trip Reports)		\$	28,945	\$ 68,814
Interoperable System for Supplies and Re-Supply Logistics Management IVRS System         \$ 19,192         \$ 33,353           IVRS Diary Activities         \$ 60,264         \$ 122,963           IVRS Diary Activities         Total Products of Efficiency Credit Sub-total         \$ 407,891         \$ 783,176           Pass-Through Expenses (Estimated)         Free           EDC         Free         Free         Free           Investigator Fees         \$ 496,650         \$ 1,002,560           Investigator Meeting Organization         \$ 21,000         \$ 21,000           Investigator Meeting Travel         \$ 47,655         \$ 49,850         \$ 30,448           Travel to Training Meetings         \$ 1,050         \$ 34,150         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100         \$ 1,050           Meetings and Teleconferences         \$ 2,260         \$ 5,745         \$ 1,050           Ivalidation         \$ 1,260         \$ 2,260         \$ 5,745           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 1,260         \$ 5,360           Lab Fees         \$ 2,200         \$ 53,3845	Early Safety Signal Detection System		\$	32,053	\$ 57,294
IVRS Object (NRS Diary Activities)         \$ 60,644         \$ 122,963           IVRS Diary Activities         Total Product (Fifticiency Credit)         \$ 407,891         783,176           PASS-Through Expenses (Estimated)         Tender (Stigger Fees)	Clinical Project Accounting System		\$	35,819	\$ 90,508
IVRS Diary Activities         \$	Interoperable System for Supplies and Re-Supply Logistics Management		\$	19,192	\$ 33,353
Total Product         4 407,891 (113,49)         783,176           Efficiency Credit         1 (113,49)         783,176           Pass-Through Expenses (Estimated)         2 94,142         7 Free           EDC         Free         Free         Free           Investigator Meeting Organization         \$ 496,650 \$ 1,002,560         \$ 1,002,560           Investigator Meeting Organization         \$ 47,565 \$ 49,350         \$ 1,002,560           Investigator Meeting Travel         \$ 84,058 \$ 370,448         \$ 370,448           Travel to Training Meetings         \$ 2,310 \$ 34,150         \$ 1,050         \$ 1,050           Travel to Client Meetings         \$ 1,260 \$ 2,100         \$ 1,050         \$ 1,0	IVRS System		\$	60,264	\$ 122,963
Pass-Through Expenses (Estimated)   Free	IVRS Diary Activities		\$	-	\$ -
Sub-ton J         294,142           Pass-Through Expenses (Estimated)           EDC         Free         Free           Investigator Fees         \$ 496,650         \$ 1,002,560           Investigator Meeting Organization         \$ 21,000         \$ 21,000           Investigator Meeting Travel         \$ 84,058         \$ 37,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 2,268         \$ 57,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ 207,900         \$ 533,845           Drug Supply         \$ 207,900         \$ 53,845           Specialty Lab/ECG         \$ 10,000         \$ 2,200           Central Pathologists         \$ 1,019,850         \$ 1,500           Other         Total Pass-Through Expenses         \$ 1,019,850         \$ 2,340,7		Total Products	\$	407,891	\$ 783,176
Pass-Through Expenses (Estimated)   Fire   Free		Efficiency Credit	\$	(113,749)	
EDC         Free         Free           Investigator Fees         \$ 496,650         \$ 1,002,560           Investigator Meeting Organization         \$ 21,000         \$ 21,000           Investigator Meeting Travel         \$ 84,055         \$ 49,350           Monitor Travel         \$ 84,058         \$ 370,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel to Audit Visits         \$ 1,050         \$ 1,050           Meetings and Teleconferences         \$ 4,778         \$ 18,199           IVRS Expenses         \$ 22,680         \$ 57,456           Printing, Shipping and Other         \$ 7,49         \$ 18,090           Printing, Shipping and Other         \$ 6,300         \$ 10,500           Regulatory and EC Fees         \$ 207,900         \$ 53,845           Drug Supply         \$ 207,900         \$ 533,845           Drug Supply         \$ 12,600         \$ 12,000           Specialty Lab/ECG         \$ 103,950         \$ -           Central Pathologists         \$ 2,500         \$ 15,750           Other         \$ 7,400         \$ 1,000           Total Pass-Through Expes         \$ 1,000,00           <		sub-total	\$	294,142	
Investigator Fees         \$ 496,650         \$ 1,002,560           Investigator Meeting Organization         \$ 21,000         \$ 21,000           Investigator Meeting Travel         \$ 47,565         \$ 49,350           Monitor Travel         \$ 84,058         \$ 370,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 4,778         \$ 18,199           VRS Expenses         \$ 22,680         \$ 7,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ 2         \$ 25,200           Specialty Lab/ECG         \$ 103,950         \$ -           Other         \$ 7         \$ 25,200           Other         \$ 7         \$ 2,340,728           Total Pass-Through Expense         \$ 1,019,850         \$ 2,340,728           Total Project Cost         \$ 2,240,002         \$ 5,740,480					
Investigator Meeting Organization         \$ 21,000         \$ 21,000           Investigator Meeting Travel         \$ 47,565         \$ 49,350           Monitor Travel         \$ 84,058         \$ 370,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 4,778         \$ 18,199           IVRS Expenses         \$ 22,680         \$ 57,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ 7.4         \$ 124,960           Specialty Lab/ECG         \$ 103,950         \$ -           Central Pathologists         \$ 2.5,200         \$ 25,200           Other         \$ 7.4         \$ 2,340,728           Total Project Cost         \$ 2,242,029         \$ 5,744,480           Less: Numoda Investment         \$ 0,100,000	EDC			Free	Free
Investigator Meeting Travel         \$ 47,565         \$ 49,350           Monitor Travel         \$ 84,058         \$ 370,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel tor Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 4,778         \$ 18,199           IVRS Expenses         \$ 22,680         \$ 57,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ -         \$ 124,960           Specialty Lab/ECG         \$ 103,950         \$ -           Central Pathologists         \$ -         \$ 25,200           Other         \$ -         \$ 1,5750           Total Project Cost         \$ 2,242,029         \$ 5,744,480           Less: Numoda Investment         \$ 2,240,029         \$ 5,744,480			\$		\$ 1,002,560
Monitor Travel         \$ 84,058         \$ 370,448           Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 4,778         \$ 18,199           VRS Expenses         \$ 22,680         \$ 7,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ 7         \$ 124,960           Specialty Lab/ECG         \$ 103,950         \$ - \$ 124,960           Central Pathologists         \$ 7         \$ 25,200           Other         \$ 7         \$ 2,340,728           Total Project Cost         \$ 2,340,728           Less: Numoda Investment         \$ (250,000)         \$ (100,000)					
Travel to Training Meetings         \$ 2,310         \$ 34,150           Travel to Client Meetings         \$ 1,050         \$ 1,050           Travel for Audit Visits         \$ 1,260         \$ 2,100           Meetings and Teleconferences         \$ 4,778         \$ 18,199           IVRS Expenses         \$ 22,680         \$ 57,456           Printing, Shipping and Other         \$ 7,749         \$ 18,900           Regulatory and EC Fees         \$ 6,300         \$ 10,500           Translation         \$ 12,600         \$ 55,260           Lab Fees         \$ 207,900         \$ 533,845           Drug Supply         \$ -         \$ 124,960           Specialty Lab/ECG         \$ 103,950         \$ -           Central Pathologists         \$ -         \$ 25,200           Other         \$ -         \$ 1,019,850         \$ 2,340,728           Total Project Cost         \$ 2,242,029         \$ 5,740,480           Less: Numoda Investment         \$ (250,000)         \$ (100,000)					
Travel to Client Meetings       \$ 1,050       \$ 1,050         Travel for Audit Visits       \$ 1,260       \$ 2,100         Meetings and Teleconferences       \$ 4,778       \$ 18,199         IVRS Expenses       \$ 22,680       \$ 57,456         Printing, Shipping and Other       \$ 7,749       \$ 18,900         Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ 2,79,900       \$ 533,845         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ 7,749       \$ 12,400         Total Pass-Through Expense       \$ 103,950       \$ -         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Travel for Audit Visits       \$ 1,260       \$ 2,100         Meetings and Teleconferences       \$ 4,778       \$ 18,199         IVRS Expenses       \$ 22,680       \$ 57,456         Printing, Shipping and Other       \$ 7,749       \$ 18,900         Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ 207,900       \$ 533,845         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ 103,950       \$ -         Other       \$ 1,019,850       \$ 2,340,728         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Meetings and Teleconferences       \$ 4,778       \$ 18,199         IVRS Expenses       \$ 22,680       \$ 57,456         Printing, Shipping and Other       \$ 7,749       \$ 18,900         Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ -       \$ 124,960         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ -       \$ 1,019,850       \$ 2,340,728         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
IVRS Expenses       \$ 22,680       \$ 57,456         Printing, Shipping and Other       \$ 7,749       \$ 18,900         Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ -       \$ 124,960         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ -       \$ 15,750         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Printing, Shipping and Other       \$ 7,749       \$ 18,900         Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ -       \$ 124,960         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ -       \$ 1,019,850       \$ 2,340,728         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Regulatory and EC Fees       \$ 6,300       \$ 10,500         Translation       \$ 12,600       \$ 55,260         Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ -       \$ 124,960         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ -       \$ 1,019,850       \$ 2,340,728         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Translation       \$ 12,600 \$ 55,260         Lab Fees       \$ 207,900 \$ 533,845         Drug Supply       \$ - \$ 124,960         Specialty Lab/ECG       \$ 103,950 \$ -         Central Pathologists       \$ - \$ 25,200         Other       \$ - \$ 15,750         Total Pass-Through Expenses       \$ 1,019,850 \$ 2,340,728         Total Project Cost       \$ 2,242,029 \$ 5,740,480         Less: Numoda Investment       \$ (250,000) \$ (100,000)	J 11 J		-	,	
Lab Fees       \$ 207,900       \$ 533,845         Drug Supply       \$ -       \$ 124,960         Specialty Lab/ECG       \$ 103,950       \$ -         Central Pathologists       \$ -       \$ 25,200         Other       \$ -       \$ 15,750         Total Pass-Through Expenses       \$ 1,019,850       \$ 2,340,728         Total Project Cost       \$ 2,242,029       \$ 5,740,480         Less: Numoda Investment       \$ (250,000)       \$ (100,000)					
Drug Supply         \$ - \$ 124,960           Specialty Lab/ECG         \$ 103,950         \$ -           Central Pathologists         \$ - \$ 25,200           Other         \$ - \$ 15,750           Total Pass-Through Expenses         \$ 1,019,850         \$ 2,340,728           Total Project Cost         \$ 2,242,029         \$ 5,740,480           Less: Numoda Investment         \$ (250,000)         \$ (100,000)					
Specialty Lab/ECG         \$ 103,950 \$ -           Central Pathologists         \$ -         \$ 25,200           Other         \$ -         \$ 15,750           Total Pass-Through Expenses         \$ 1,019,850 \$ 2,340,728           Total Project Cost         \$ 2,242,029 \$ 5,740,480           Less: Numoda Investment         \$ (250,000) \$ (100,000)					
Central Pathologists         \$ - \$ 25,200           Other         \$ - \$ 15,750           Total Pass-Through Expenses         \$ 1,019,850         \$ 2,340,728           Total Project Cost         \$ 2,242,029         \$ 5,740,480           Less: Numoda Investment         \$ (250,000)         \$ (100,000)					124,960
Other         \$ - \$ 15,750           Total Pass-Through Expenses         \$ 1,019,850         \$ 2,340,728           Total Project Cost         \$ 2,242,029         \$ 5,740,480           Less: Numoda Investment         \$ (250,000)         \$ (100,000)				103,950	-
Total Pass-Through Expenses   1,019,850   2,340,728				-	
Total Project Cost \$ 2,242,029 \$ 5,740,480 Less: Numoda Investment \$ (250,000) \$ (100,000)	Other	m . 15 m . 1 =			
Less: Numoda Investment \$ (250,000) \$ (100,000)		Total Pass-Through Expenses			
. (					 
Net Total Due from Advaxis \$ 1,992,029 <u>\$ 5,640,480</u>	Less: Numoda Investment		\$	(250,000)	\$ (100,000)
Net Total Due from Advaxis \$ 1,992,029 \$ 5,640,480					
	Net Total Due from Advaxis		\$	1,992,029	\$ 5,640,480

NET TOTAL DUE from ADVAXIS

(210,597) \$ 1,992,029 -9.56% -10.57% 7,632,509

5,640,480 \$

Trial Pricing - Advaxis (Two Trial Scenario)  Budget Summary		INDIA Trial Numoda Contract Value		Efficiencies from US Trial Numoda Contract Value		Discounted India Trial Numoda Contract Value	_	US Trial  Numoda  Contract  Value		Grand Total- Both Trials Numoda Contract Value
NUMODA GENERAL CONTRACTOR AND INTEGRATION SERVICES:		value	_	value	_	varue	_	varue	_	value
Role-Based Portals Connecting to Interoperable Neural Network	\$	30,457	\$	(9,359)	\$	21,098	\$	55,404	\$	76,502
	\$	45,943	\$	(12,673)	\$	33,270	\$	63,323	\$	
All Custom Complete Integration and Interoperability Ongoing Consolidation and Reconciliation	\$	45,943 21,003	\$		\$	14.627	\$	37,493	\$	116,593 52,120
	\$	27,748	\$	(6,376) (8,753)	\$	18,995	\$	47,552	\$	56,547
Planning, Procurement & Contracting Clinical Project Accounting Vendor Management, Documentation, Monitoring & Financial	Ф	27,740	Ф	(0,/33)	Ф	10,993	Ф	47,332	Ф	30,347
Reconciliation	\$	27,748	\$	(0.072)	\$	18,675	\$	50,494	\$	69,169
CLINICAL PROFESSIONAL SERVICES:	Ф	27,740	Ф	(9,073)	Ф	10,075	Ф	30,494	Ф	09,109
	\$	122,362	\$	0	\$	122,362	\$	250,604	\$	372,966
Start Up, Regulatory & Site Management Monitoring	э \$	254,613	\$	0	\$	254,613	\$	1,288,014	\$	1,522,627
	\$	151,489	\$	(49,908)	\$	101,581	\$	396,950	\$	498,531
Project Management	э \$	226,063	\$	(46,940)	\$	179,123	\$	289,759	\$	
Data Management	\$		\$		\$	79,123	\$		\$	468,882
Safety, Medical & Scientific Services	Ф	79,898	-	0				183,446		283,344
Biostatistics & Medical Writing	\$	190,460	\$	0	\$	190,460	\$	227,804	\$	418,264
SUBTOTAL PROFESSIONAL FEES	\$	1,177,784	\$	(143,082)	\$	1,034,702	\$	2,890,843	\$	3,935,545
De Jest Communica		Numoda Contract Value		Numoda Contract Value		Numoda Contract Value		Numoda Contract Value		Numoda Contract Value
Budget Summary	_	varue	_	value	_	varue	_	varue	_	varue
NUMODA SYSTEMS AND REPORTING TOOLS:		40.050		(2.00.1)		10.051		25.250		20.442
Screening and Enrollment systems	\$	16,858	\$	(3,804)	\$	13,054	\$	25,359	\$	38,413
Site compliance Tools	\$	34,659	\$	(7,554)	\$	27,105	\$	55,546	\$	82,651
Real Time Reporting Tools (with Document Management system)	\$	27,202	\$	(7,762)	\$	19,440	\$	57,072	\$	76,512
Integrated, Web-Based Monitoring system (with Centralized Trip Reports)	\$	28,945	\$	(9,087)	\$	19,858	\$	66,814	\$	86,672
Early Safety Signal Detection System	\$	32,053	\$	(7,094)	\$	24,959	\$	57,294	\$	82,253
Clinical Project Accounting System	\$	35,819	\$	(10,955)	\$	24,864	\$	90,508	\$	115,372
Interoperable system for Supplies and Re-Supply Logistics Management	\$	19,192	\$	(4,536)	\$	14,656	\$	33,353	\$	48,009
									-	
IVRS System	\$	60,264	\$	(16,723)	\$	43,541	\$	122,963	\$	156,504
IVRS Diary Activities	\$	0	\$	0	\$	0	\$	0	\$	0
	-									
IVRS Diary Activities	\$	0	\$	0	\$	0	\$	0	\$	0
IVRS Diary Activities  SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS,	\$	0 254,992	\$	0 (67,515)	\$	0 187,477	\$	508,909	\$	0 686,386
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary	\$	0 254,992	\$	0 (67,515)	\$	0 187,477	\$	508,909	\$	0 686,386
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated)	\$ \$ \$	0 254,992 1,432,776 Numoda Contract Value	\$ \$	(210,596)  Numoda Contract Value	\$ \$	1,222,180  Numoda Contract Value	\$ \$	3,399,752  Numoda Contract Value	\$ \$	0 686,386 4,621,932 Numoda Contract Value
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC	\$ \$ \$	0 254,992 1,432,776 Numoda Contract Value	\$ \$ \$	0 (67,515) (210,596) Numoda Contract Value	\$ \$ \$	0 187,477 1,222,180 Numoda Contract Value	\$ \$ \$	0 508,909 3,399,752 Numoda Contract Value	\$ \$ \$	0 686,386 4,621,932 Numoda Contract Value
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees	\$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650	\$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value	\$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650	\$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560	\$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization	\$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000	\$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0	\$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000	\$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000	\$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Fees Investigator Meeting Organization Investigator Meeting Travel	\$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665	\$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0	\$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565	\$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350	\$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel	\$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058	\$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value	\$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058	\$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448	\$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings	\$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310	\$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310	\$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150	\$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary  VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Client Meetings	\$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050	\$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050	\$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050	\$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Investigator Travel Travel to Training Meetings Travel to Client Meetings Travel for Audit Visits	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260	\$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260	\$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100	\$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Client Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary  VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Audit Visits Meetings and Teleconferences IVRS Expenses	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses IVRS Expenses	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 2,100 18,199 57,456 18,900	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Client Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary  VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Monitor Travel Travel to Crianing Meetings Travel to Client Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 2,100 18,199 57,456 18,900 10,500 55,260 533,845	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Client Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Training Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply Specialty Lab/ECG	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 4,778 22,680 7,749 6,300 12,600 207,900 0 103,850	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,950	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960 103,950
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Investigator Meeting Travel Monitor Travel to Client Meetings Travel to Client Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply Specialty Lab/ECG Central Pathologists	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,850 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$\\\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,950 0	\$\\\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960 0 25,200	\$\\\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960 103,950 25,200
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Training Meetings Travel to Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply Specialty Lab/ECG Central Pathologists Other	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,850 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,950 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960 0 25,200 15,750	\$\\ \$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960 103,950 25,200 15,760
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary  VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Training Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply Specialty Lab/ECG Central Pathologists Other  TOTAL ESTIMATED PASS THROUGH COSTS	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 4,778 22,680 7,749 6,300 12,600 207,900 0 103,850 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,950 0 0 1,019,850	\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\ \\$\\	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960 0 25,200 0 25,200 2,340,728	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960 103,950 25,200 15,760 3,360,578
SUBTOTAL NUMODA SYSTEMS AND REPORTING TOOLS  TOTAL GENERAL CONTRACTOR SERVICES, INTEGRATIONS, PROFESSIONAL FEES, AND SYSTEMS AND TOOLS  Budget Summary VALUE ADDED SUPPLIER ITEMS (Estimated) EDC Investigator Fees Investigator Meeting Organization Investigator Meeting Travel Monitor Travel Travel to Training Meetings Travel to Training Meetings Travel to Client Meetings Travel for Audit Visits Meetings and Teleconferences IVRS Expenses Printing, Shipping and Other Regulatory and EC Fees Translation Lab Fees Drug Supply Specialty Lab/ECG Central Pathologists Other	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 254,992 1,432,776 Numoda Contract Value 0 496,650 21,000 47,665 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,850 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 (67,515) (210,596) Numoda Contract Value 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 187,477 1,222,180 Numoda Contract Value 0 496,650 21,000 47,565 84,058 2,310 1,050 1,260 4,778 22,680 7,749 6,300 12,600 207,900 0 103,950 0	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	0 508,909 3,399,752 Numoda Contract Value 0 1,002,560 21,000 49,350 370,448 34,150 1,050 2,100 18,199 57,456 18,900 10,500 55,260 533,845 124,960 0 25,200 15,750	\$\\ \$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$	0 686,386 4,621,932 Numoda Contract Value 0 1,499,210 42,000 96,915 454,506 36,460 2,100 3,360 22,977 80,136 26,649 16,800 67,850 741,745 124,960 103,950 25,200 15,760

2,202,626

#### Notes TO PROJECT BUDGET:

- (A) Budget for Trial 1 includes an Efficiency Credit of \$210,597 that is given with the understanding that Numoda will be providing services to Advaxis for two trials, as long as Numoda's work on the first Trial has been satisfactory. The actual, final scope of the second trial is yet to be determined, therefore prices for Trial 2 shown above, may be adjusted, if the scope is changed ..
- (B) Budget for Trial 1 is based on the protocol dated May 30, 2009. Budget for Trial 2 is based on protocol dated December 3, 2008.
- (C) Per the Master Agreement, paragraph 7.0 Change Orders, it is understood that Advaxis may seek to materially change the scope of Services and/or project assumptions agreed upon in the Project Agreement for either trial, such as can occur when there are amendments to the Protocol. Both parties agree to negotiate in good faith to reach an agreement on a budget and assumptions for such changes.
- (D) The \$350,000 Numoda Investment (which includes the \$150,000 Investment committed in previously executed LOI documents between the parties) is payable to Numoda in Advaxis common stock, based on the average of the five (5) days stock price, prior to the execution of a Stock Purchase Agreement.

5,640,480

#### **Attachment D:** PAYMENT SCHEDULE

212,029 Start-Up Payment (July 15, 2009)

#### Trial 1 Lm-LLO-E7-15 (110 patients/12 sites, in India)

	Easy Level Monthly Payment Plan assumes 20 monthly installments of \$89,000 each	
2009 – 4 months		\$ 356,000
	Beginning Sept. 2009 thru April, 2011	
2010 – 12 months		\$ 1,068,000
2011 – 4 months		\$ 356,000
Sub-total Monthly Payments (20)		\$ 1,780,000
TOTAL TRIAL 1 -India		\$ 1,992,029
Start-Up Payment (August 15, 2009)		\$ 564,480
Trial 2 Lm-LLO-E7-07 (80 patients/20 sites, in USA)		
2009 – 3 Months		\$ 423,000
	Easy Level Monthly Payment Plan assumes 36 monthly	
2010 – 12 months	installments of \$141,000 each	\$ 1,692,000
2011 – 12 months	Beginning Sept, 2009 thru August, 2012	\$ 1,692,000
2012 – 9 months		\$ 1,269,000
Sub-total Monthly Payments (36)		\$ 5,076,000

Notes to Payment Schedule:

(a) Monthly Payments are due an the 15th of each month.

TOTAL TRIAL 2 – US

- (b) Numoda shall mail and/or email invoices to Advaxis per Advaxis' instructions.
- (c) Advaxis shall make all payments payable to Numoda Corporation, by wire transfer, EFT, or ACH. Advaxis shall send funds to Harleysville National Bank, as follows:

Bank: Harleysville National Bank

ABA Number

- xxxxxxxxx

Account Name - Numoda Corporation

Account Number - xxxxxxxxx

## Attachment E: Transfer of Regulatory Obligations

- 1.0 Numode will retain records and reports associated with the Project in accordance with 21 CFR 312.57(b)
- 2.0 Numoda will conduct the services set forth in this Project Agreement in accordance with Clinical Protocols, Lm-LLO-E7-15 and Lm-LLO-E7-07.

# CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18.U.S.C. 7350 (SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

#### I, Thomas Moore, certify that:

- 1. I have reviewed this report on Form 10-Q/A for the quarter ended April 30, 2012 of Advaxis, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

June 26, 2012

/s/ Thomas Moore	
Name: Thomas Moore	
Title: Chief Executive Officer	

#### CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18.U.S.C. 7350 (SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

#### I, Mark J. Rosenblum, certify that:

- 1. I have reviewed this report on Form 10-Q/A for the quarter ended April 30, 2012 of Advaxis, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

June 26, 2012

/s / Mark J. Rosenblum Name: Mark J. Rosenblum Title: Chief Financial Officer

#### CERTIFICATION-PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

The undersigned as Chief Executive Officer of Advaxis, Inc. (the "Company"), does hereby certify that the foregoing Amendment No. 1 to Quarterly Report on Form 10-Q/A of the Company for the quarter ended April 30, 2012:

- (1) Fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) Fairly presents, in all material respects, the financial condition and result of operations of the Company.

June 26, 2012

#### /s/ Thomas Moore

Thomas Moore

Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

#### CERTIFICATION-PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

The undersigned as the Chief Financial Officer of Advaxis, Inc. (the "Company"), does hereby certify that the foregoing Amendment No. 1 to Quarterly Report on Form 10-Q/A of the Company for the quarter ended April 30, 2012:

- (1) Fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) Fairly presents, in all material respects, the financial condition and result of operations of the Company.

June 26, 2012

#### /s/ Mark J. Rosenblum

Mark J. Rosenblum Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.